$SYRE

Spyre Therapeutics (SYRE) reported that its anti-IL-23 antibody, SPY003, met primary endpoints in a Phase 2 trial, showing a 10.0-point reduction in Robart’s Histopathology Index score. This follows successful results for SPY001 and SPY002, completing proof-of-concept for all three molecules in its IBD portfolio. The company has $1.1 billion in cash, enough to fund operations into 2029. Part B of the SKYLINE trial, testing drug combinations, is still enrolling, with data expected in 2027. Spyre

Spyre Therapeutics (SYRE) reported Phase 2 trial results for SPY003 in ulcerative colitis patients, showing a 10-point decline in tissue inflammation and 20% clinical remission. The study lacked a control arm, and further testing is needed. The company has $1.15B in cash and expects funding into 2029. Part B of the trial is enrolling, with results expected in 2027.

Guggenheim named Spyre Therapeutics (SYRE) its top biotech pick after positive Phase II trial data for SPY003, showing 20% clinical remission in ulcerative colitis. The firm highlights durability as a key advantage. Part B of the study is enrolling, with results expected in 2027. Guggenheim maintains a positive rating despite a recent downgrade from Wolfe Research.

Spyre Therapeutics (SYRE) CFO Scott L. Burrows exercised options for 7,500 shares at $14.50 each and sold 25,732 shares, including 18,232 to cover taxes, at prices between $86.25 and $89.35 under a 10b5-1 plan. He retains options for 337,357 shares.

Spyre Therapeutics (SYRE) officer Heidy King-Jones exercised options for 28,399 shares at $14.50 each and sold them at prices up to $90.00, following a pre-arranged Rule 10b5-1 plan. The sales occurred on September 1-2, 2026, with weighted-average prices ranging from $85.71 to $88.69. Gross proceeds totaled approximately $2.48 million, with a pre-tax spread of about $2.07 million.

King-Jones Heidy (See Remarks) sold 28,399 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $87.35 ($86.40–$90.00, $2.48M total) across 5 trades over 2026-09-01 to 2026-09-02 under a Rule 10b5-1 trading plan.

Burrows Scott L (Chief Financial Officer) sold 25,732 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $88.75 ($86.25–$89.35, $2.28M total) across 5 trades over 2026-09-01 to 2026-09-02 under a Rule 10b5-1 trading plan.

Turtle Cameron (Chief Executive Officer) sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $87.29 ($86.36–$89.07, $1.31M total) across 4 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Stocks rose slightly on mixed US economic news. Crude oil prices fell over 8% this week on easing Middle East tensions. S&P 500 Q2 earnings growth is tracking at 32%, driven by AI spending. Summit Therapeutics (SMMT) and Semtech (SMTC) gained over 8% on positive earnings. Kohl's (KSS) and Intuit (INTU) fell over 4% on weak forecasts.

Guggenheim maintains a buy rating on Spyre Therapeutics, citing positive Phase II SKYWAY-RA results for SPY072, despite discontinuing the rheumatoid arthritis program. The firm projects the stock to settle in the $90-95 range, with valuation based on the inflammatory bowel disease program. Other analysts have mixed views, with Wolfe Research downgrading and Mizuho raising its price target to $120.